By blocking TREK-1, PE-22-28: Increases neuronal excitability : Reduces potassium efflux, depolarizing neurons toward firing threshold Enhances serotonergic transmission : TREK-1 is expressed on serotonergic neurons in the dorsal raphe nucleus
Ozempic (semaglutide) : approved for type 2 diabetes Wegovy (semaglutide) : approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with weight-related comorbidities Mounjaro (tirzepatide) : approved for type 2 diabetes Zepbound (tirzepatide) : approved for chronic weight management under the same criteria as Wegovy If you dont have diabetes, the weight-management brands (Wegovy, Zepbound) are what your doctor would prescribe, assuming you meet the criteria
Theodora (Dora) Manolakou, Jianyu Shen, Sanjay Boddul, Martina Samiotaki, Angelos Panagias, George Sentis, Tarcilia Aparecida Silva, Alexandra Argyriou, Dionysis Nikolopoulos, kumar sanjiv, Karine Chemin, Fredrik Wermeling, Martin Henriksson, Ana Slipicevic, Per-Johan Jakobsson, Katerina Chatzidionysiou, Thomas Helleday To view or add a comment, sign in Zenagamtide : A Potential Game-Changer in Type 2 Diabetes and Obesity Management by Novo Nordisk The era of single-molecule, dual-pathway therapies is rapidly advancing
Here are the most notable findings from a study involving mice with growth hormone deficiencya condition that leads to stunted growth, reduced lean mass, and increased abdominal fat [17]: Enhanced growth and lean body mass: Growth hormone deficient (GHD) mice exhibited approximately 20% less lean body mass than normal, struggling to attain regular body size or weight
